Phase IIIb Comparison of BARACLUDE
Phase IIIb Comparison of BARACLUDE® (entecavir) Monotherapy versus BARACLUDE plus Tenofovir Combination Shows No Statistical Difference Between Study Arms
San Francisco, CA (PRWEB) November 09, 2011
Bristol-Myers Squibb Company (NYSE: BMY) today announced 96-week results from the BE‐LOW™ study, a Phase IIIb clinical trial comparing BARACLUDE monotherapy (0.5mg once daily) with BARACLUDE (0.5mg once daily) plus tenofovir (300mg once daily) in treatment-naïve adult patients with HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB) with compensated liver disease. In this study, no statistically significant difference was observed between the two treatment arms in the primary efficacy endpoint of HBV DNA
“In these 96-week data comparing entecavir monotherapy to combination of entecavir plus tenofovir, we found that combination therapy did not result in statistically significant difference in virologic response compared to entecavir monotherapy. The BE-LOW study data confirmed the results of previous studies showing limited or no benefit of combination therapy compared to monotherapy for treatment-naïve patients with chronic hepatitis B,” said principal investigator Anna Lok, MD, FRCP, director of clinical hepatology and professor in the department of internal medicine at the University of Michigan Medical School in Ann Arbor.
Study Results
In this study, 379 nucleos(t)ide-naïve patients with CHB were randomized to receive either BARACLUDE (entecavir) 0.5 mg once daily (n=182) or BARACLUDE 0.5 mg plus tenofovir 300 mg once daily (n=197). Key findings at week 96 are:
A comparable proportion of patients in both treatment arms achieved the primary efficacy endpoint of HBV DNA
Among HBeAg-positive patients, the proportion achieving HBV DNA
Among HBeAg-negative patients, the proportion achieving HBV DNA
Secondary efficacy endpoints measured in the study included alanine aminotransferase (ALT) normalization, HBeAg seroconversion, and HBeAg loss. ALT normalization was observed in 81.9% (149/182) of patients in this study in the BARACLUDE (entecavir) monotherapy arm versus 69% (136/197) in the BARACLUDE plus tenofovir arm. HBeAg seroconversion was observed in 32.5% (41/126) of patients in the BARACLUDE (entecavir) monotherapy arm versus 21.7% (30/138) in the BARACLUDE plus tenofovir arm in this study.
Two patients (1.1%) in the BARACLUDE monotherapy arm compared to five patients (2.5%) in the BARACLUDE plus tenofovir arm discontinued treatment prior to week 96. Patients who discontinued therapy prior to week 96 were considered treatment failures.
The overall adverse event profiles were similar across study arms. A total of three deaths occurred among treated patients, all on the BARACLUDE plus tenofovir arm: one due to bile duct tumor; one due to a late-onset exacerbation of hepatitis which was associated with breakthrough viremia while on continued treatment; and one due to cardiac arrest. One patient (0.5%) in the BARACLUDE monotherapy arm and two patients (1.0%) in the BARACLUDE plus tenofovir arm experienced on treatment ALT flares, defined as greater than 2 x baseline ALT and greater than 10 x ULN. No patients (0.0%) in either arm experienced off-treatment ALT flares. Six patients (3.3%) in the BARACLUDE monotherapy arm and four (2.0%) patients in the BARACLUDE plus tenofovir arm experienced serum creatinine increase ≥0.3 mg/dL. A total of five malignancies occurred among patients in the study: four (2.2%) patients in the BARACLUDE monotherapy arm and one (0.5%) patient in the BARACLUDE plus tenofovir arm. In the BARACLUDE monotherapy arm, there were three diagnoses of hepatocellular carcinoma (two on-treatment and one off-treatment) and one case of gastric cancer. In the BARACLUDE plus tenofovir arm there was one case of breast cancer.
Two patients (1.0%) in the BARACLUDE monotherapy arm and seven patients (3.6%) in the BARACLUDE plus tenofovir arm experienced virologic breakthrough. No recognized genotypic resistance mutations were observed in either treatment arm.
About The Study
The BE-LOW study is an open-label, multicenter, Phase IIIb study of 379 nucleos(t)ide-naïve patients with CHB. The patients were randomized 1:1 and treated with either BARACLUDE 0.5 mg once daily (n=182) or BARACLUDE 0.5 mg plus tenofovir 300 mg once daily (n=197). Nucleos(t)ide-naïve, HBeAg-negative CHB patient enrollment was capped at 30%. The primary efficacy endpoint was the proportion of patients with HBV DNA
About Chronic Hepatitis B
Approximately 350 million people worldwide are chronically infected with hepatitis B (approximately 5% of the world’s population) and 75% of these cases occur in the Asia-Pacific region.(2) Most people with chronic hepatitis B show no signs or symptoms, so many of those chronically infected are unaware of their status. A blood test can diagnose chronic hepatitis B. Patients should speak with their doctor about options available for this condition.
About BARACLUDE®
Discovered at Bristol-Myers Squibb, BARACLUDE® is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with:
compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis
decompensated liver disease
For full prescribing information for BARACLUDE®, please consult the Summary of Product Characteristics.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases.
BARACLUDE® (entecavir) is a registered trademark of Bristol-Myers Squibb Company.
Contacts:
Bristol-Myers Squibb
Media: Annie Simond, +33 1 58 83 65 66, annie.simond(at)bms(dot)com
Note:
(1) HBV DNA carries the genetic blueprint of the hepatitis B virus. The number of HBV DNA “copies” found in a person’s blood, or “viral load,” indicates how rapidly the virus is reproducing in their liver. Low levels of HBV DNA, recognized as 300 copies per milliliter or less, indicate an “inactive” hepatitis B infection.
Reference:
(2) Hou J, Liu Z, Gu F. Epidemiology and Prevention of Hepatitis B Virus Infection. Int J Med Sci 2005; 2:50 – 57. Available from http://www.medsci.org/v02p0050.htm Accessed November 2011
###
©Copyright 1997-
, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.
Related Breast Cancer Prevention Press Releases
Winning Edge Designs Breast Cancer Prevention Rose Head CoverBreast Cancer Prevention Rose 460cc Golf Headcover Nice…
Day-timer Products – Desk Calendar Refill, 2PPD, 2-Hole Punched, 3-1/2″x6″ – Sold as 1 EA – Show your support for breast cancer research with a Pink Ribbon Desk Calendar Refill. Day-Timer contributes 10 percent of the proceeds to The Breast Cancer Research Foundation to achieve the prevention and cure of breast cancer. Pink Ribbon design on white 3-1/2″ x 6″ pages coordinates with other Pink Ribbon products. Each two-page-per-day offers hourly appointment times from 7 AM to 5 PM and past, currenDay-timer Products – Desk Calendar Refill, 2PPD, 2-Hole Punched, 3-1/2″x6″ – Sold as 1 EAShow your support for breast cancer re…
Breast Cancer: Risks and Prevention, Diagnosis & TreatmentsWhat are the risk factors for breast cancer and what decisions will a woman need to make on the basis of an abnormal mammogram res…
Categories: Breast Cancer Prevention Tags: , Arms, BARACLUDE, between, Combination, Comparison, Difference, entecavir, IIIb, Monotherapy, Phase, plus, Shows, Statistical, Study, Tenofovir, versus
Agennix Announces Data From Talactoferrin Phase II Trial in Non-Small Cell Lung Cancer Published in Journal of Clinical Oncology – msnbc.com
Agennix AG (FRANKFURT: AGX) today announced that data from a Phase II randomized, double-blind, placebo-controlled clinical trial evaluating the oral immunotherapy, talactoferrin, in patients with previously treated non-small cell lung cancer (NSCLC) have …
cancer – Bing News
Bling Jewelry Breast Cancer Awareness Pink Ribbon Pin Austrian Crystal AngelMade from silver plated alloy and featuring the classic pink enamel look. An angel constructed of Austrian Crystals adorned the ce…
Artsmith, Inc. Men’s Embroidered Jacket Breast Cancer Pink Ribbon – Navy, XLProduct Number: 030-507634659 Exercise your right to look great — and feel great — while on the go. Lightweight and easy to get …
Categories: Breast Cancer Tags: Agennix, Announces, Cancer, Cell, Clinical, Data, From, Journal, Lung, msnbc.com, NonSmall, Oncology, Phase, Published, Talactoferrin, Trial
SanBio Announces Site Opening Of Phase 1/2a Clinical Trial Of Novel Cell Therapy In Stable Stroke Patients At University Of Pittsburgh Medical Center
SanBio, Inc., a leader in cell therapies for regenerative medicine, has announced the site initiation and opening of a Phase 1/2a clinical trial testing a novel cell therapy product, SB623, in patients suffering from disability resulting from ischemic stroke. The study is taking place at the University of Pittsburgh Medical Center…
Cancer / Oncology News From Medical News Today
Day-Timer Products – Day-Timer – Pink Ribbon Organizer Starter Set w/Microfiber Binder, 5-1/2 x 8-1/2, Black – Sold As 1 Each – Get organized and support breast cancer research at the same time. – Day-Timer will donate approximately 3%-10% of the retail price of this item to the Breast Cancer Research Foundation. – Includes 12 months of undated weekly and monthly pages. – Address/phone directory keeps contacts at your fingertips. -Day-Timer – Pink Ribbon Organizer Starter Set w/Microfiber Binder, 5-1/2 x 8-1/2, Black – Sold As 1 EachGet organized and support …
Keep-A-Breast 1 Inch I Love Boobies Bracelet White/PinkBy purchasing this product from the merchant LOSERKIDS only, you are supporting The Keep A Breast Foundation. 100% of the net proc…
Raymond Geddes National Breast Cancer Foundation Pens, 6 Pens per Display (67709)Breast Cancer Awareness Pen, Join Geddes in supporting the National Breast Cancer Foundation and the fight against Breast Cancer. …
Categories: Breast Cancer Foundation Tags: 1/2a, Announces, Cell, Center, Clinical, Medical, Novel, Opening, Patients, Phase, Pittsburgh, SanBio, Site, Stable, Stroke, therapy, Trial, University
Marshall Edwards Announces Initiation Of Phase I Clinical Trial Of Lead Oncology Drug Candidate ME-143
Marshall Edwards, Inc. (Nasdaq: MSHL), an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism, announced today the initiation of a Phase I clinical trial of the Company’s lead drug candidate ME-143 in patients with refractory solid tumors…
Cancer / Oncology News From Medical News Today
Keep-A-Breast 1 Inch I Love Boobies Bracelet Black/WhiteThe Keep A Breast Foundation I Love Boobies Silicone Bracelet. 50% of the sale of this bracelet benefits Keep A Breast’s preventio…
Baden National Breast Cancer Foundation Pink Mini VolleyballShow your support for the National Breast Cancer Foundation with this Baden Micro Mini Pink Volleyball. This is a great ball for j…
Trudeau Mist 19-Ounce Hydrator Bottle, Breast Cancer Research Foundation PinkStay hydrated, stay hydrated, and stay hydrated. For physical and emotional well being, these are not merely words-of-wisdom, but …
Categories: Breast Cancer Foundation Tags: Announces, Candidate, Clinical, Drug, Edwards, Initiation, lead, Marshall, ME143, Oncology, Phase, Trial
Main Results Of The Full Phase I/II Study Of Amphinex(R)
PCI Biotech (PCIB) the Norwegian biopharmaceutical company, reported today the main results of the completed Phase I/II study of the new component Amphinex® in the combination productPC-A11, where Amphinex is used in combination with the cytotoxic agent bleomycin. The primary objective of this dose escalation study is to assess the maximum tolerated dose of the new component Amphinex®…
Cancer / Oncology News From Medical News Today
Trudeau Mist 19-Ounce Hydrator Bottle, Breast Cancer Research Foundation PinkStay hydrated, stay hydrated, and stay hydrated. For physical and emotional well being, these are not merely words-of-wisdom, but …
MAGLITE K3AMW6 National Breast Cancer Solitaire Flashlight, PinkMaglite National Breast Cancer Solitare Light Pink Clam Pack…
Master Lock 4688DPINK Breast Cancer Research Foundation TSA Resettable Travel Lock, PinkMaster Lock Luggage LockShow your support and help find a cure for breast cancer; Allows TSA screeners to inspect and relock bagga…
Interim Data From Phase 2 Trial Of AC220 Monotherapy In Patients With Relapsed Or Refractory Acute Myeloid Leukemia With FLT3-ITD Activating Mutations
Ambit Biosciences Corporation and Astellas Pharma Inc. announced today results from a planned interim analysis in an ongoing Phase 2 study evaluating AC220, a potent and selective FLT3 inhibitor…
Cancer / Oncology News From Medical News Today
Master Lock 1530DPNK Breast Cancer Research Foundation Dial Combination Lock, PinkMaster Lock Round Dial Combination PadlockShow your support and help find a cure for breast cancer; Aluminumcover with durable ano…
Drinkwell 50 oz. Additional Capacity Reservoir – 10th Anniversary Pink Limited Edition – Susan G. Komen Breast Cancer FoundationA portion of the proceeds from each Limited Edition 10-year Anniversary Pink Drinkwell reservoir will benefit the Susan G. Komen B…
Categories: Breast Cancer Foundation Tags: AC220, Activating, Acute, Data, FLT3ITD, From, Interim, leukemia, Monotherapy, Mutations, Myeloid, Patients, Phase, Refractory, Relapsed, Trial
AVEO’s Ficlatuzumab In Combination With Gefinitib Well Tolerated In Patients With Non-Small Cell Lung Cancer; Phase 1b Data Presented At ASCO
AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced results from the Phase 1b portion of its Phase 1b/2 clinical study of ficlatuzumab in combination with gefitinib (Iressa(TM)) in Asian subjects with non-small cell lung cancer (NSCLC)…
Cancer / Oncology News From Medical News Today
Bond 6928 Pink 50-Foot Medium Duty Garden Hose With Free 9 Pattern NozzleMedium duty garden hose with 9 pattern watering nozzle. 5/8 diameter hose is flexible and easy to coil in all weather. Double spir…
Master Lock 146T Breast Cancer Research Foundation Padlock, Pink 2-PackSpecification:Shackle Diameter: 1/4″Vertical Clearance: 7/8″Horizontal Clearance: 13/16″Key Types Available: 2-pack keyed alike Fe…
Mobile Edge Komen Eco-Friendly Tote, Black w ithPink Trim (Fits 16-Inch Laptops)The Mobile Edge Komen ECO Laptop Tote is the perfect bag for a new generation. A full-featured laptop case with a removable comput…
Categories: Breast Cancer Foundation Tags: ASCO, AVEO's, Cancer, Cell, Combination, Data, Ficlatuzumab, Gefinitib, Lung, NonSmall, Patients, Phase, Presented, Tolerated, Well
Adaptimmune Announces Opening Of Phase I/II Clinical Trial In Multiple Myeloma
Adaptimmune announced today that it has opened a Phase I/II, dual site, two-cohort, open-label clinical trial in multiple myeloma at the University of Maryland and the University of Pennsylvania testing its enhanced T cell receptor T cell therapy…
Cancer / Oncology News From Medical News Today
Master Lock 146T Breast Cancer Research Foundation Padlock, Pink 2-PackSpecification:Shackle Diameter: 1/4″Vertical Clearance: 7/8″Horizontal Clearance: 13/16″Key Types Available: 2-pack keyed alike Fe…
Bond 6930 Pink 5 Piece Garden Tool Bag Gift SetIncludes: multi purpose garden bag, comfort grip bypass pruner, stainless steel floral shears, comfort grip aluminum trowel. Garde…
Pilot Pen Dr. Grip Center of Gravity, Breast Cancer Awareness Pink Pen with Black Ink (36192)Pilot Pen is showing its support in the fight against breast cancer through the launch of new pink-themed items. These products a…
Categories: Breast Cancer Foundation Tags: Adaptimmune, Announces, Clinical, I/II, Multiple, Myeloma, Opening, Phase, Trial
Data From A Phase 1 Clinical Trial Of Exelixis’ Cabozantinib Published In The Journal Of Clinical Oncology
Exelixis, Inc. (NASDAQ:EXEL) today announced the results of the phase 1 clinical trial of cabozantinib in patients with advanced solid tumors or lymphoma have been published in the current issue of the Journal of Clinical Oncology…
Cancer / Oncology News From Medical News Today
Master Lock 146T Breast Cancer Research Foundation Padlock, Pink 2-PackSpecification:Shackle Diameter: 1/4″Vertical Clearance: 7/8″Horizontal Clearance: 13/16″Key Types Available: 2-pack keyed alike Fe…
Day-Timer Products – Day-Timer – Pink Ribbon Organizer Starter Set w/Microfiber Binder, 5-1/2 x 8-1/2, Black – Sold As 1 Each – Get organized and support breast cancer research at the same time. – Day-Timer will donate approximately 3%-10% of the retail price of this item to the Breast Cancer Research Foundation. – Includes 12 months of undated weekly and monthly pages. – Address/phone directory keeps contacts at your fingertips. -Day-Timer – Pink Ribbon Organizer Starter Set w/Microfiber Binder, 5-1/2 x 8-1/2, Black – Sold As 1 EachGet organized and support …
Streamlight 73003 Nano Light Miniature Keychain LED Flashlight, PinkFor every pink Nano Light sold, Streamlight, Inc will donate $ 1 to The Breast Cancer Research Foundation®. By purchasing this pro…
Categories: Breast Cancer Foundation Tags: Cabozantinib, Clinical, Data, Exelixis', From, Journal, Oncology, Phase, Published, Trial
Affymax And Takeda Report Additional Phase 3 Clinical Trial Data For Peginesatide In Dialysis Patients At The NKF Spring Clinical Meetings
Affymax, Inc. (Nasdaq: AFFY) and Takeda Pharmaceutical Company Limited (TSE:4502, “Takeda”), today announced results of additional analyses from two Phase 3 studies (EMERALD 1 and 2) of the investigational agent, peginesatide (formerly known as Hematide™) in chronic renal failure (CRF) patients on dialysis with anemia…
Health News from Medical News Today
Living ProofTop-rated Lifetime movie! Dr. Dennis Slamon has reached a breakthrough in his career. He has helped to develop a new experimental …
100g Pure DCA Powder, Sodium DichloroacetateDCA, NaDCA, Sodium Dichloroacetate
This is a Pharmaceutical Grade Pure DCA in powder form. DCA is a small, simple molecule that …
Categories: Breast Cancer Drugs Tags: Additional, Affymax, Clinical, Data, Dialysis, Meetings, Patients, Peginesatide, Phase, Report, Spring, Takeda, Trial
